rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CGTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      What Makes Cognition Therapeutics (CGTX) a New Buy Stock

      Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Nov 10Yahoo FinanceCGTX
      Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
      Nov 9Yahoo FinanceCGTX
      Cognition Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceCGTX
      Cognition Therapeutics Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceCGTX
      Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
      Nov 5Yahoo FinanceCGTX
      Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
      Nov 2Yahoo FinanceCGTX
      Cognition aligns with FDA on phase 3 trial design for DLB
      Oct 22Investing.comCGTX
      H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent grant
      Oct 15Investing.comCGTX
      Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development
      Oct 13Yahoo FinanceCGTX
      Cognition Therapeutics receives patent for zervimesine form
      Oct 13Investing.comCGTX
      H.C. Wainwright reiterates Cognition Therapeutics stock rating ahead of FDA meeting
      Oct 5Investing.comCGTX
      Cognition Therapeutics schedules FDA meeting on DLB drug trial
      Sep 29Investing.comCGTX
      Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

      PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer

      Sep 8Yahoo FinanceCGTX
      Best Penny Stocks of 2026: Are They a Good Investment? | The Motley Fool

      Looking to invest in penny stocks? See which affordable stocks are standing out and showing potential for growth.

      Aug 23The Motley FoolCGTXIVPXPON

      This is the newest page. Registered accounts read further back.